naloxone hydrochloride

FDA Drug Profile — NALOXONE HYDROCHLORIDE, Naloxone Hydrochloride, naloxone hydrochloride, RiVive

Drug Details

Generic Name
naloxone hydrochloride
Brand Names
NALOXONE HYDROCHLORIDE, Naloxone Hydrochloride, naloxone hydrochloride, RiVive
Application Number
ANDA211951
Sponsor
AMERISOURCE BERGEN
NDC Codes
25
Dosage Forms
SPRAY, INJECTION, SOLUTION, INJECTION
Routes
NASAL, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS, PARENTERAL
Active Ingredients
NALOXONE HYDROCHLORIDE

Indications and Usage

INDICATIONS & USAGE Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including, propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine and butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock. (see CLINICAL PHARMACOLOGY ; Adjunctive Use in Septic Shock).

Warnings

WARNINGS Drug Dependence Naloxone hydrochloride should be administered cautiously to persons including newborns of mothers who are known or suspected to be physically dependent on opioids. In such cases an abrupt and complete reversal of opioid effects may precipitate an acute withdrawal syndrome. The signs and symptoms of opioid withdrawal in a patient physically dependent on opioids may include, but are not limited to, the following: body aches, diarrhea, tachycardia, fever, runny nose, sneezing, piloerection, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In the neonate, opioid withdrawal may also include: convulsions, excessive crying, and hyperactive reflexes. Repeat Administration The patient who has satisfactorily responded to naloxone hydrochloride should be kept under continued surveillance and repeated doses of naloxone hydrochloride should be administered, as necessary, since the duration of action of some opioids may exceed that of naloxone hydrochloride. Respiratory Depression due to Other Drugs Naloxone hydrochloride is not effective against respiratory depression due to non-opioid drugs and in the management of acute toxicity caused by levopropoxyphene. Reversal of respiratory depression by partial agonists or mixed agonist/antagonists, such as buprenorphine and pentazocine, may be incomplete or require higher doses of naloxone. If an incomplete response occurs, respirations should be mechanically assisted as clinically indicated.